Comparative Pharmacology
Head-to-head clinical analysis: FERROUS CITRATE FE 59 versus INDIUM IN 111 OXYQUINOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERROUS CITRATE FE 59 versus INDIUM IN 111 OXYQUINOLINE.
FERROUS CITRATE FE 59 vs INDIUM IN 111 OXYQUINOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferrous citrate Fe 59 is a radioactive isotope of iron used for diagnostic purposes. It is incorporated into hemoglobin in red blood cells, allowing visualization of erythropoiesis and imaging of the reticuloendothelial system.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
Ferrous citrate Fe 59 is a radioactive diagnostic tracer, not a therapeutic iron supplement. Typical adult dose: 2-10 µCi (0.074-0.37 MBq) intravenously as a single dose for iron absorption or red cell utilization studies.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
None Documented
None Documented
Terminal elimination half-life of Fe-59 from plasma is approximately 1.5-2 hours for free iron, but for total body iron, it is about 5-6 hours initially, followed by a slow phase of 6-10 days due to redistribution to storage sites. Clinically, the long half-life allows imaging of erythropoiesis over days.
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Fe-59 is primarily excreted via feces (80-90%) as unabsorbed iron, with minor renal excretion (<5%) and negligible biliary elimination. Absorbed iron is incorporated into hemoglobin and red blood cells, with loss via desquamation (~1 mg/day) not reflected in excretion fractions.
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical